Medicine and HealthNature Nanotechnology
CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics
L. Hao, R. T. Zhao, et al.
This research introduces a groundbreaking method for detecting and differentiating disease states using chemically stabilized nucleic acids multiplexed with synthetic biomarkers. Conducted by renowned researchers including Liangliang Hao and Sangeeta N. Bhatia, this innovative approach utilizes urine analysis through CRISPR-Cas detection mechanisms, paving the way for a convenient point-of-care diagnostic tool.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
CRISPR-Cas Systems: A Promising Tool for Viral Disease Detection and Therapy
M.s., M.k., et al.
Engineering and Technology
Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges
R. P. Singh, A. Natarajan, et al.
Medicine and Health
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies
K. Challa, D. Paysan, et al.
Medicine and Health
CAR T-Cell Therapy for Cancer: Latest Updates and Challenges, with a Focus on B-Lymphoid Malignancies and Selected Solid Tumours
H. K. Tang, C. Tang, et al.
